Showing results (1221-1230 of 2,824) with videos related to

Sort By:
Pageof 283
Cytotherapy|March 25, 2022
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomesAlice Bertaina, Allistair Abraham, Carmem Bonfim, et al.
Cytotherapy|March 25, 2022
Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project teamRonit Reich-Slotky, Ljiljana V Vasovic, Kevin J Land, et al.
Cytotherapy|April 4, 2022
Standardization of cellular therapy terminology, coding and labeling: a reviewPaul Ashford, Sallie Allman, Stella Larsson, et al.
Cytotherapy|September 22, 2021
Adenovirus vector-attributed hepatotoxicity blocks clinical application in gene therapyZeng Wang, Xiaozhan Zhang
Cytotherapy|March 4, 2010
Overcoming the barriers to umbilical cord blood transplantationSusan Staba Kelly, Simrit Parmar, Marcos De Lima, et al.
Cytotherapy|March 4, 2010
Differential expression of biofunctional GM1 and GM3 gangliosides within the plastic-adherent multipotent mesenchymal stromal cell populationDaniel Freund, Ana-Violeta Fonseca, Peggy Janich, et al.
Cytotherapy|March 4, 2010
Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells does not have synergistic effects after spinal cord injury in the ratTakashi Amemori, Pavla Jendelová, Katerina Růzicková, et al.
Cytotherapy|March 4, 2010
Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cellsQiang Xu, Xiaodan Jiang, Yiquan Ke, et al.
Cytotherapy|March 4, 2010
Superparamagnetic iron oxide nanoparticles may affect endothelial progenitor cell migration ability and adhesion capacityJin-Xiu Yang, Wei-Liang Tang, Xing-Xiang Wang
Cytotherapy|July 1, 2017
Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II studyManuel Jurado, Claudia De La Mata, Antonio Ruiz-García, et al.
Pageof 283